Wells Fargo’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-454
| Closed | -$104 | – | 7336 |
|
|
2024
Q4 | $104 | Hold |
454
| – | – | ﹤0.01% | 6411 |
|
|
2024
Q3 | $976 | Hold |
454
| – | – | ﹤0.01% | 6127 |
|
|
2024
Q2 | $2.34K | Sell |
454
-163
| -26% | -$856 | ﹤0.01% | 5990 |
|
|
2024
Q1 | $3.3K | Buy |
617
+77
| +14% | +$532 | ﹤0.01% | 5955 |
|
|
2023
Q4 | $4.2K | Sell |
540
-101
| -16% | -$346 | ﹤0.01% | 5984 |
|
|
2023
Q3 | $2.53K | Sell |
641
-104
| -14% | -$389 | ﹤0.01% | 6059 |
|
|
2023
Q2 | $2.35K | Sell |
745
-1
| -0.1% | -$3 | ﹤0.01% | 6189 |
|
|
2023
Q1 | $1.99K | Buy |
746
+46
| +7% | +$178 | ﹤0.01% | 6221 |
|
|
2022
Q4 | $2.51K | Buy |
700
+1
| +0.1% | +$4 | ﹤0.01% | 5957 |
|
|
2022
Q3 | $4K | Buy |
699
+663
| +1,842% | +$5.39K | ﹤0.01% | 6001 |
|
|
2022
Q2 | $0 | Sell |
36
-626
| -95% | -$5.86K | ﹤0.01% | 7671 |
|
|
2022
Q1 | $8K | Sell |
662
-2,039
| -75% | -$36.5K | ﹤0.01% | 6360 |
|
|
2021
Q4 | $88K | Buy |
2,701
+2,686
| +17,907% | +$109K | ﹤0.01% | 5711 |
|
|
2021
Q3 | $1K | Hold |
15
| – | – | ﹤0.01% | 6826 |
|
|
2021
Q2 | $1K | Sell |
15
-881
| -98% | -$52.1K | ﹤0.01% | 6768 |
|
|
2021
Q1 | $67K | Sell |
896
-6,725
| -88% | -$699K | ﹤0.01% | 5670 |
|
|
2020
Q4 | $827K | Sell |
7,621
-565
| -7% | -$51.6K | ﹤0.01% | 4171 |
|
|
2020
Q3 | $724K | Sell |
8,186
-125
| -2% | -$14.2K | ﹤0.01% | 4095 |
|
|
2020
Q2 | $886K | Buy |
8,311
+6,034
| +265% | +$542K | ﹤0.01% | 3906 |
|
|
2020
Q1 | $135K | Sell |
2,277
-343
| -13% | -$23.3K | ﹤0.01% | 4909 |
|
|
2019
Q4 | $181K | Sell |
2,620
-145
| -5% | -$8.8K | ﹤0.01% | 5012 |
|
|
2019
Q3 | $287K | Sell |
2,765
-202
| -7% | -$19.1K | ﹤0.01% | 4747 |
|
|
2019
Q2 | $274K | Sell |
2,967
-239
| -7% | -$16.6K | ﹤0.01% | 4785 |
|
|
2019
Q1 | $293K | Buy |
3,206
+721
| +29% | +$50.2K | ﹤0.01% | 4636 |
|
|
2018
Q4 | $138K | Buy |
2,485
+1,331
| +115% | +$101K | ﹤0.01% | 5126 |
|
|
2018
Q3 | $137K | Sell |
1,154
-715
| -38% | -$82.9K | ﹤0.01% | 5205 |
|
|
2018
Q2 | $191K | Buy |
1,869
+56
| +3% | +$6.93K | ﹤0.01% | 5060 |
|
|
2018
Q1 | $235K | Buy |
1,813
+350
| +24% | +$38.3K | ﹤0.01% | 4890 |
|
|
2017
Q4 | $143K | Sell |
1,463
-259
| -15% | -$34.8K | ﹤0.01% | 5145 |
|
|
2017
Q3 | $253K | Buy |
1,722
+312
| +22% | +$58.7K | ﹤0.01% | 4793 |
|
|
2017
Q2 | $227K | Hold |
1,410
| – | – | ﹤0.01% | 4700 |
|
|
2017
Q1 | $225K | Buy |
+1,410
| New | +$172K | ﹤0.01% | 4740 |
|
Other funds holding SYRS
BBA
1CM
XT
Wells Fargo's SYRS Position: Q1 2025 in Review
Wells Fargo sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 454 shares — an estimated $104 sold.
Wells Fargo first reported a position in SYRS in Q1 2017 and held it in 32 quarters. The position peaked at $886K in Q2 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Wells Fargo reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Wells Fargo sold 454 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $104.
- Wells Fargo first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 32 quarters.
- Wells Fargo's Syros Pharmaceuticals, Inc. Common Stock position peaked at $886K in Q2 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.